Navigation Links
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer

SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Ambit Biosciences Inc. today announced the appointment of Michael A. Martino as President, Chief Executive Officer and member of the Board of Directors. Martino brings to Ambit a nearly 30-year track record in leading privately held and publicly traded life sciences companies through late-stage clinical development, fundraising, commercial and business development activities, including new product launches and mergers and acquisitions.  He replaces Alan Lewis, Ph.D., who announced his departure earlier this year and recently left the company after supporting the transition to Martino's appointment.

"We are pleased that Mike, having completed diligence sees what we see: a promising lead drug candidate, quizartinib, with compelling interim data in a high medical need population and valuable earlier-stage assets that together make up an impressive pipeline," said Faheem Hasnain, Ambit's Chairman.  "Mike is joining a talented and committed Ambit team that has successfully moved three drug candidates into the clinic, any one of which could be a lead drug in an earlier stage company, and discovered several promising preclinical compounds. Mike will provide the necessary experience and leadership to drive quizartinib through the approval process and prioritize and focus development of the pipeline."

Martino said, "I am pleased to join Ambit and continue the development of its rich pipeline of early and late-stage programs.  There is tremendous promise in quizartinib where the interim Phase 2 data suggest durable leukemic control in relapsed/refractory acute myeloid leukemia patients with FLT3-ITD mutations who otherwise have very limited treatment options available.  I also look forward to focusing and leading the development of our earlier clinical stage assets, AC430 and AC480, which are targeted at large patient populations with unmet needs."

From 1999 to 2008, Martino served as President and Chief Executive Officer of Sonus Pharmaceuticals Inc., a publicly traded cancer therapeutics company.  During his tenure, he refocused the company on oncology drug development, and oversaw development of the company's lead cancer therapeutic through a pivotal Phase 3 trial conducted under a special protocol assessment.  In addition, he played an integral role in establishing and managing collaborations with partners, raising capital from public markets and ultimately completing a reverse merger with Oncogenex Pharmaceuticals Inc.  

In 2009, Martino joined with the cofounders of Arzeda Corp., a privately held company focused on enzyme design and development using technology licensed from the University of Washington.  During his tenure as the company's first CEO, he oversaw the company's start-up and fundraising activities, both through private investment and collaborations. In 2010, Martino joined CareFusion Corporation and held multiple positions including Senior Vice President and General Manager of diagnostics and Senior Vice President of Innovation, Business Development and Strategy.  Earlier in his career, he held multiple positions during a 17-year tenure at Mallinckrodt in strategic planning, business development, marketing, and general management, where he completed multiple acquisitions and licensing agreements and led a major restructuring of the company.

Martino received an M.B.A. from Virginia Tech and a bachelor's degree from Roanoke College. He currently serves on the Board of Directors of Arzeda Corp.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as mono-therapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.  Interim data from the first two patient cohorts demonstrated a composite complete response rate in 45 percent of patients, a median duration of response of 12.1 weeks, and survival of 24.7 weeks.  No treatment-related deaths have been reported.  The most common treatment-related adverse events included nausea, vomiting, fatigue and febrile neutropenia.  Several cases of QTc prolongation were reported in the study, but most resolved following a dose adjustment. AML is one of the most common types of blood cancers in adults, with ITD mutations in the FLT3 gene occurring in 25 percent to 30 percent of AML patients.  FLT3 ITD mutations confer poor prognosis, with early relapse and lower survival following treatment with existing therapies, including chemotherapy and hematopoietic stem cell transplant.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications.  Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML.  Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.  In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor.  Ambit also has a preclinical candidate, CEP-32496, a BRAF inhibitor licensed to Cephalon. For more information, visit

Media Contact:
Ian Stone or David Schull
Russo Partners
(619) 308-6541
(212) 845-4271

Investor Contact:
Cindy McGee
Russo Partners
(619) 308-6538

SOURCE Ambit Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ambit Biosciences Announces Transition in Company Leadership
2. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
3. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
5. Neurocrine Biosciences Reports Third Quarter 2011 Results
6. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
7. GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
8. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
9. Amarillo Biosciences Issues Corporate Update
10. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
11. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
Breaking Biology Technology:
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
Breaking Biology News(10 mins):